Plain-English translation of NCT05379712 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two specialized medical foods—Resource® Support Plus and BOOST® Soothe—can help head and neck cancer patients keep up their nutrition and oral intake during chemotherapy and radiation therapy. These are specially formulated drinks designed to be easier to consume when cancer treatment causes mouth pain, difficulty swallowing, or taste changes. The study compares patients who receive these drinks from the start of treatment versus those who follow standard nutritional care, then later switches everyone to the drinks.
Head and neck cancer patients undergoing radiation and chemotherapy often struggle to eat regular food due to severe side effects like mouth sores, difficulty swallowing, and altered taste. When patients lose weight and become malnourished during treatment, it can weaken their immune system and make treatment harder to tolerate. This trial exists to see whether easy-to-use medical food drinks can help patients maintain their nutrition and strength throughout their cancer treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups at the start of your cancer treatment. One group receives the two specialized medical food drinks right away (along with regular dietary counseling), while the other group follows standard nutritional care for the first 7 weeks, then receives the drinks for the remaining weeks. The study lasts 14 weeks total, and you will have weekly check-ins with an oncology nutritionist. You will simply drink the medical foods as often as you prefer, alongside your regular eating (if you can), and the research team will monitor your weight and nutrition levels throughout your treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Canada
Phase
Testing effectiveness
Sponsor
AHS Cancer Control Alberta
Enrollment target
~81 participants
Started
October 2024
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vickie Baracos
Cross Cancer Institute, Alberta Health Services
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.